An update on the management of relapsed and primary refractory Hodgkin’s disease
Author:
- 30 April 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 54-59
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialThe Lancet, 2002
- A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelBlood, 2001
- High‐dose therapy for Hodgkin's diseaseBritish Journal of Haematology, 1999
- ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin’s DiseaseBlood, 1999
- ESHAP is an active regimen for relapsing Hodgkin's diseaseAnnals of Oncology, 1999
- High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapyAnnals of Oncology, 1996
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patientsBlood, 1993
- Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: The Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiationAnnals of Oncology, 1991
- Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantationBlood, 1989